685. Early Experience with a Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent Clostridioides difficile

BACKGROUND: Fecal Microbiota, live-jslm (RBL) is a rectally administered, pre-packaged, live biotherapeutic approved in November 2022 for the prevention of recurrence of Clostridioides difficile infection (rCDI) in adults. As the first FDA-approved microbiota product, this new agent may pose challen...

Descripción completa

Detalles Bibliográficos
Autores principales: Hengel, Richard L, Krishnan, Sujatha, Rosenberg, Jonathan A, Ritter, Timothy E, Baker, Kathy A, Van Anglen, Lucinda J, Guo, Amy, Moosapanah, Mielad, Yang, Min, Garey, Kevin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677259/
http://dx.doi.org/10.1093/ofid/ofad500.747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677259/
http://dx.doi.org/10.1093/ofid/ofad500.747

Ejemplares similares